baber/WOPTO huggingface dataset:
Patent AU-776562-B2 (AU)
Title: Plasmid maintenance system for antigen delivery
Inventor: GALEN JAMES E
IPC: A61P31/04
Filed: 1999-12-02
Granted: 2004-09-16
Abstract: The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.
Patent AU-686394-B2 (AU)
Title: Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
Inventor: DAN MICHAEL D
IPC: A61K38/00
Filed: 1995-06-16
Granted: 1998-02-05
Abstract: The variable chains of two human monoclonal antibodies (HMAbs) of the IgM isotype are characterized by elucidation of cDNAs encoding those chains. The HMAbs are specific against cell cycle independent, glioma-associated antigen, and the antibodies do not recognize cultured normal human astrocytes. Immunoconjugates based on the sequences identified should target both proliferating and non-proliferating glioma cells in vivo, thus providing a valuable adjunctive therapy in the treatment of these tumors.
Patent AU-775536-B2 (AU)
Title: Heterocyclic amine modified siloxanes
Inventor: POLICELLO GEORGE A
IPC: C09K23/54
Filed: 2000-02-16
Granted: 2004-08-05
Abstract: The present invention teaches heterocyclic amine modified siloxanes and their use, a preferred of which is as adjuvants for pesticides. The heterocyclic amine modified siloxanes have siloxane backbones with pendant, terminal or intermediate heterocyclic amine groups, which may contain one or more heteroatoms, i.e., nitrogen, sulfur or oxygen. The heterocyclic amine groups or the siloxane may be functionalized further with alkyl or alkyleneoxide groups.
Patent AU-612777-B2 (AU)
Title: Molecular sieve arrangement
Inventor: LAUBE HANS-JURGEN
IPC: A62B23/00
Filed: 1989-01-06
Granted: 1991-07-18
Abstract: PCT No. PCT/CH89/00002 Sec. 371 Date Sep. 6, 1989 Sec. 102(e) Date Sep. 6, 1989 PCT Filed Jan. 6, 1989 PCT Pub. No. WO89/06156 PCT Pub. Date Jul. 13, 1989.A molecular sieve material is combined with a porous carrier material. The pores of the molecular sieve material are impermeable to molecules or organisms having a size equal to or greater than that of the water molecule either because the molecular sieve material is selected so as to have pores which are smaller than such molecule or because the pores of the molecular sieve material are closed by a film. The pores of the molecular sieve material thus remain unoccupied and are able to exert an attractive force on molecules or organisms which are to be captured. The pores of the carrier material are designed to accept molecules or organisms having a size equal to or greater than that of the water molecule so that, when such molecules or organisms are attracted by the molecular sieve material, they can be trapped in the carrier material.
Patent AU-718488-B2 (AU)
Title: Method of digital demodulation
Inventor: BELVEZE FABRICE
IPC: H04L1/06
Filed: 1997-07-24
Granted: 2000-04-13
Abstract: The method involves a receiver which performs N demodulations, forming a number of binary symbol estimates. Each estimate is a real number, with the sign used to represent the most probable value. The receiver estimates the value of a bit in the range using an algorithm which investigates the difference between estimated and verified bits to provide the bit value which has the maximum likelihood of being correct.
Patent AU-761882-B2 (AU)
Title: Implant
Inventor: BRANDAU WOLFGANG
IPC: A61M36/12
Filed: 2000-02-17
Granted: 2003-06-12
Abstract: An implant is suggested having a receptacle space for a therapeutic agent, which can leave the receptacle space through a permeable element. For exact dosage, an open-pore diffusion element is suggested as the permeable element, wherein the pore walls are chemically modified for control of the diffusion.
Patent AU-744044-B2 (AU)
Title: Short peptides for treatment of neurological degenerative diseases
Inventor: PERT CANDACE
IPC: A61K38/00
Filed: 1999-04-06
Granted: 2002-02-14
Abstract: The HIV-1 envelope protein gpl20 is toxic to rodent and human neurons by indirect mechanisms requiring accessory glial cells. Chemokines are known to block gpl20 interactions with chemokine receptors on T cells, macrophages, and microglia, thereby preventing viral infection. Gpl20-induced neuronal killing in rat hippocampal cultures was partially or completely prevented by specific short peptides related to chemokines, specifically KEYFTS and LESYT. These peptides thus have use in the treatment of neurological degenerative diseases having symptoms associated with neuronal cell death.
Patent AU-715666-B2 (AU)
Title: Water suction powered automatic swimming pool cleaning system
Inventor: HENKIN MELVYN L
IPC: E04H4/16
Filed: 1997-06-25
Granted: 2000-02-10
Abstract: Automatic swimming pool cleaning method and apparatus for cleaning a water pool (1) contained in an open vessel (2) defined by a containment wall (3) having a bottom (4) and side (5) portions utilizing a unitary structure or body (6) configured for immersion in a pool (1) for selective operation proximate the water surface (7) in a surface cleaning mode or proximate to the interior wall surface portions (8) in a wall surface cleaning mode.
Patent AU-658731-B2 (AU)
Title: Expandable garment hanger
Inventor: HUNT WILLIAM JOSEPH
IPC: A47G25/62
Filed: 1993-04-28
Granted: 1995-04-27
Abstract: PCT No. PCT/GB90/00353 Sec. 371 Date Sep. 10, 1991 Sec. 102(e) Date Sep. 10, 1991 PCT Filed Mar. 8, 1990 PCT Pub. No. WO90/10408 PCT Pub. Date Sep. 20, 1990.An expandable garment hanger with which the invention is concerned has a body (1), a hook (2) on the body to suspend the hanger and a pair of movable arms (3,4), slidably mounted on the body. The arms are arranged to move in opposite directions. A locking device (8,9) is located on the body (1) of the hanger so as to lock the movable arms relative to the body. The locking device is movable along a path parallel to the path along which the arms are movable. A biasing device, preferably a spring (27), is provided for biasing the locking device (9,9) against movement in one direction so that when the arm of the hanger is set and locked in position the arms of the hanger are movable against the biasing force of the spring (27). The hanger conveniently supports garments of varying waist widths and maintains the hanger at the desired widths once the garment is mounted on the hanger but also allows the garment to be removed from the hanger by a small inward force applied to the end of the arm.
Patent AU-671645-B2 (AU)
Title: Topical application composition
Inventor: GROSS UDO
IPC: A61Q1/00
Filed: 1993-06-24
Granted: 1996-09-05
Abstract: A topical application composition with light-screening properties in a special application form is disclosed. The problem with known light-screening agents containing native melanine as active substance is an insufficient melanin transport to its site of activity. The invention solves this problem with a topical application composition characterized by a content of melanin dissolved or dispersed in one or several fluorocarbons available as asymmetrical lamellar phospholipid aggregates in an aqueous system, together with a phospholipid. The particle size of the aggregates lies in the 200 to 3000 nm range.
Patent AU-622720-B2 (AU)
Title: The use of oxidized polyamines, especially nn'-bis-(3- propionaldehyde)-1-4-diaminobutane (sperminedialdehyde) as immunosuppressive agents
Inventor: LAU CATHERINE Y
IPC: C07C217/40
Filed: 1989-10-24
Granted: 1992-04-16
Abstract: Oxidized polyamines of the Formula:  OCH - ALK<1> - NR<2> - CH2 - ALK<2> - CH2 - NR<2> - Z  wherein  ALK<1> is independently alkylene;  R<2> is independently hydrogen or -CH2R<3>;  R<3> is independently alkyl;  ALK<2> is alkylene;  Z is H or ALK<1> -CHO; and their acid addition salts are disclosed as immunosuppressive agents.
Patent AU-725961-B2 (AU)
Title: Process for the formation of a fuel mixture and for its ignition in a pre-chamber that is open toward the cylinders
Inventor: RIGAZZI PIER ANDREA
IPC: F02B19/12
Filed: 1997-11-03
Granted: 2000-10-26
Abstract: PCT No. PCT/IB97/01362 Sec. 371 Date Apr. 29, 1999 Sec. 102(e) Date Apr. 29, 1999 PCT Filed Nov. 3, 1997 PCT Pub. No. WO98/20240 PCT Pub. Date May 14, 1998Process for ensuring the mixing of a predetermined quantity of liquid or gaseous fuel with the air that is contained in a pre-chamber with one end that is open toward cylinders of an alternative internal-combustion engine, as well as the ignition of the mixture with the fuel being injected axially from closed end of the pre-chamber by an injector that is actuated by a predefined surplus of pressure compared to that which is present in the pre-chamber itself, the injection is a accomplished during the terminal phase of the compression half-cycle, whereby the injector and surplus are such as to ensure the fuel jet which is injected is completely evaporated and/or mixed with the air that is contained in the pre-chamber at the moment when it reaches the open end of the pre-chamber and which, during its translation motion, mixes with the above-mentioned air according to mixture richness values that can be represented by a predetermined curve that rises from injection point (A) towards center (C) of the open-end of the pre-chamber.
Patent AU-692996-B2 (AU)
Title: Composition for inhibiting intimal hyperplasia using PDGF antagonists and heparin
Inventor: HART CHARLES E
IPC: C07K16/28
Filed: 1995-12-20
Granted: 1998-06-18
Abstract: Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.
Patent AU-526571-B2 (AU)
Title: Alkyl derivatives of c-076 compounds
Inventor: FISHER MICHAEL HERBERT
IPC: A61K31/355
Filed: 1979-07-25
Granted: 1983-01-20
Abstract: The invention provides derivatives of C-076, which is a series of macrolides, having certain hydrocarbon substituents. The hydrocarbon substituents in general are alkyl groups which may be straight or branched and may optionally be substituted with phenyl. The substituted C-076 compounds are prepared by various procedures depending upon the position of the reaction site, and the particular C-076 compound being substituted. The compounds thus produced are of formula: 
<CHEM>
 where the broken line indicates that a single or a double bond is present in the 22(23) position; R1 is hydroxy, loweralkanoyloxy or hydrocarbonoxy and is present only when the broken line indicates a single bond; R2 is iso-propyl or sec-butyl; R3 is hydrogen, methyl, loweralkanoyl or a hydrocarbon;
 R is hydrogen, loweralkanoyl, a hydrocarbon, 
<CHEM>
 where R4 is hydrogen, loweralkanoyl or a hydrocarbon, and
 R5 is hydrogen or methyl; and the said hydrocarbonoxy group of R1 is an alkoxy of from 1 to 10 carbon atoms or an alkoxy of from 1 to 10 carbon atoms or an alkoxy of from 1 to 10 carbon atoms substituted by phenyl and the said hydrocarbon groups of R and R4, which are the same or different, are alkyl of from 1 to 10 carbon atoms or alkyl of from 1 to 10 carbon atoms substituted by phenyl; and the said hydrocarbon group of R3 is an alkyl of from 2 to 10 carbon atoms or an alkyl of from 1 to 10 carbon atoms substituted by phenyl; provided that at least one of the R, R1, R3, and R4 groups is or contains a hydrocarbon group or R5 is methyl. They have profound anthelmintic, insecticidal, ectoparasiticidal and acaracidal activity and compositions for such uses are also disclosed.
Patent AU-648016-B2 (AU)
Title: Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in antiviral therapy
Inventor: SPRINGER TIMOTHY ALAN
IPC: A61K39/00
Filed: 1990-03-15
Granted: 1994-04-14
Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.
Patent AU-579223-B2 (AU)
Title: Swivelable single axle railcar truck and railcar
Inventor: PATON H NEIL
IPC: B61F5/30
Filed: 1986-02-07
Granted: 1988-11-17
Abstract: The truck includes two parallel damper ramp supports connected together by a transverse tie assembly. A single wheeled axle is pivotally supported from the damper ramp supports in spaced apart parallel alignment with the transverse tie assembly by two independently sprung and damped radius arms. A swivel assembly is mounted by the transverse tie assembly in overlying relation with the axle. Two yaw control assemblies respectively act between the damper ramp supports and an overhead railcar body. Each of the yaw control assemblies includes a yaw damper that provides either a damping force or both a damping force and a self-centering force in response to rotative movement of the truck. A railcar equipped with two such trucks also is disclosed.
Patent AU-776306-B2 (AU)
Title: Self-adjusting pliers
Inventor: SEBER BRETT P
IPC: B25B7/12
Filed: 2000-06-15
Granted: 2004-09-02
Abstract: A self-adjusting pliers is operable to grasp a workpiece between an upper jaw and a lower jaw. The pliers includes an upper arm having a first end and a second end, with the upper jaw at the first end. A jaw arm has a first end and a second end. The second end of the jaw arm is pivotably connected to the upper arm at a main pivot adjacent to the second end of the upper arm, so that the first end of the jaw arm is movable in a circular arc relative to the main pivot. The lower jaw is at the first end of the jaw arm in movable facing relation to the upper jaw so that the workpiece may be grasped between the upper jaw and the lower jaw. An engagement mechanism releasably engages the jaw arm to the upper arm at an engagement position responsive to a movement of the jaw arm relative to the upper arm and responsive to a size of the workpiece grasped between the upper jaw and the lower jaw, to thereby prevent rotation of the jaw arm relative to the upper arm.
Patent AU-670486-B2 (AU)
Title: Composite panels having two outer layers and a core
Inventor: EHRAT RAINER
IPC: B32B27/18
Filed: 1994-03-11
Granted: 1996-07-18
Abstract: Composite panels having high fire protection performance and comprising two outer layers and a core, with the core containing a core mixture and the core mixture containing aluminium hydroxide in compacted form, light fillers, if appropriate finely divided or splintery aluminium hydroxide, if desired magnesium hydroxide and binder based on polymers. The composite panels are suitable, for example, as facing panels for above-ground buildings.
Patent AU-769357-B2 (AU)
Title: Methods for preparation of lipid-encapsulated therapeutic agents
Inventor: MAURER NORBERT
IPC: A61K9/133
Filed: 2000-07-14
Granted: 2004-01-22
Abstract: Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.
Patent AU-681396-B2 (AU)
Title: 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
Inventor: ABOOD NORMAN ANTHONY
IPC: C07C271/22
Filed: 1994-03-30
Granted: 1997-08-28
Abstract: PCT No. PCT/US94/03259 Sec. 371 Date May 23, 1995 Sec. 102(e) Date May 23, 1995 PCT Filed Mar. 30, 1994 PCT Pub. No. WO94/22820 PCT Pub. Date Oct. 13, 1994This invention relates to compounds having the following formula   <IMAGE>   or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions of such phenylamidines derivatives, and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.
Patent AU-678236-B2 (AU)
Title: 3-(hetero)aryl carboxylic acid derivatives, methods of preparing them and intermediates used in their preparation
Inventor: BAUMANN ERNST
IPC: C07D409/12
Filed: 1994-04-13
Granted: 1997-05-22
Abstract: PCT No. PCT/EP94/01141 Sec. 371 Date Oct. 19, 1995 Sec. 102(e) Date Oct. 19, 1995 PCT Filed Apr. 13, 1994 PCT Pub. No. WO94/25442 PCT Pub. Date Nov. 10, 19943-(Het)arylcarboxylic acid derivatives of the formula I    <IMAGE>  I  where R is formyl, CO2H or a radical hydrolyzable to COOH and the other substituents have the following meanings: R2 and R3 are each halogen, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio; X is nitrogen or CR14, where R14 is hydrogen or, together with R3, forms an alkylene or alkenylene chain, in each of which a methylene group is replaced by oxygen; R4 is phenyl or naphthyl, each of which is unsubstituted or substituted or an unsubstituted or substituted five-membered or six-membered heteroaromatic structure containing one to three nitrogen atoms or one sulfur or oxygen atom; R5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl or phenyl; R6 is C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkynyl or C3-C4-cyclo-alkyl, each of which may be mono- or polysubstituted; Y is sulfur, oxygen or a single bond; and Z is sulfur or oxygen; with the proviso that R6 is not unsubstituted C1-C4-alkyl when R4 is unsubstituted phenyl, Z is oxygen and simultaneously R5 is methyl or hydrogen.
Patent AU-539208-B2 (AU)
Title: Phosphate ester lubricant
Inventor: HELLSTEN KARL MARTIN EDVIN
IPC: C10M173/00
Filed: 1981-02-10
Granted: 1984-09-13
Abstract: During mechanical working, an aqueous lubricant composition is used as a lubricating and cooling agent, which contains an ether phosphate as a lubricating agent. A concentrate suitable for use as a lubricant after dilution with water is also described.
Patent AU-760218-B2 (AU)
Title: The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Inventor: LEVIN JEREMY IAN
IPC: A61K31/63
Filed: 1998-04-14
Granted: 2003-05-08
Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF- alpha  converting enzyme (TACE, tumor necrosis factor- alpha  converting enzyme) of formula (B) wherein (B) is (1), (2), or (3); P and Q are (4) or (5), provided that when P is (4), Q is (5), and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R<1>; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; (6) is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R<1>; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R<1>; R<1> is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, -(CH2)nZ, -OR<2>, -CN, -COR<2>, perfluoroalkyl of 1-4 carbon atoms, -CONR<2>R<3>, -S(O)xR<2>-OPO(OR<2>)OR<3>, -PO(OR<2>)R<3>, -OC(O)NR<2>R3, -COOR<2>, -CONR<2>R<3>, -SO3H, -NR<2>R<3>, -NR<2>COR<3>, -NR<2>COOR<3>, -SO2NR<2>R<3>, -NR<2>CONR<2>R<3>, -NR<2>C(=NR<3>)NR<2>R<3>, -SO2NHCOR<4>, -CONHSO2R<4>, -tetrazol-5-yl, -SO2NHCN, -SO2NHCONR<2>R<3>, or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R<2>; R<2> and R<3> are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R<4> is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R<5> is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n = 1-6; x = 0-2 or a pharmaceutically acceptable salt thereof.
Patent AU-736584-B2 (AU)
Title: Drug delivery via therapeutic hydrogels
Inventor: COSMO FRANK DI
IPC: A61L29/14
Filed: 1998-04-15
Granted: 2001-08-02
Abstract: The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.
Patent AU-676583-B2 (AU)
Title: Aqueous anionic polyurethane dispersions
Inventor: DUAN YOULU
IPC: C08G18/83
Filed: 1994-06-07
Granted: 1997-03-13
Abstract: Improved aqueous anionic polyurethane dispersions with a high crystallization rate, low heat activation temperature, high green strength, stability at low pH, which show good compatibility with other water based polymers and with crosslinkers. The aqueous anionic polyurethane dispersions have high heat resistance after curing or blending with a crosslinker.
Patent AU-711626-B2 (AU)
Title: Type CC chemokine-like protein
Inventor: IMAI TOSHIO
IPC: C07K14/52
Filed: 1996-09-27
Granted: 1999-10-21
Abstract: An isolated novel type CC chemokine-like protein which is expressed from peripheral blood mononuclear cells under an immunological stimulus and has a cell migration activity; a DNA encoding the protein; an expression vector and a transformant containing the DNA; a process for producing a recombinant protein by using the transformant; and a pharmaceutical composition containing the protein.